ADC Therapeutics (ADCT) Share-based Compensation (2020 - 2026)
ADC Therapeutics (ADCT) posted Share-based Compensation of $2.4 million for Q1 2026, up 262.85% sequentially from $673000.0 in Q4 2025, and up 0.87% YoY from $2.4 million in Q1 2025.
ADC Therapeutics (ADCT) Share-based Compensation (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $2.4 million in Q1 2026.
- Quarterly Share-based Compensation rose 0.87% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (down 21.57% YoY) and the FY2025 annual result came in at $6.9 million, up 5.13% from the prior year.
- Share-based Compensation rose to $2.4 million in Q1 2026 per ADCT's latest filing, from $673000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $14.6 million in Q3 2022 and troughed at $158000.0 in Q1 2024.
- A 5-year average of $4.6 million and a median of $2.2 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation plunged 98.04% in 2024, then surged 1432.28% in 2025.
- Over 5 years, Share-based Compensation stood at $7.5 million in 2022, then plunged by 70.56% to $2.2 million in 2023, then declined by 27.21% to $1.6 million in 2024, then tumbled by 58.35% to $673000.0 in 2025, then soared by 262.85% to $2.4 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.4 million, $673000.0, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | 4.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.55 Mn |
| Jun 30, 2026 | 4.55 Mn |
| Mar 31, 2026 | 2.44 Mn |
| Mar 31, 2026 | 2.44 Mn |
| Dec 31, 2025 | 673,000.00 |
| Dec 31, 2025 | 673,000.00 |
| Sep 30, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 2.81 Mn |
| Sep 30, 2024 | 2.81 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Mar 31, 2024 | 158,000.00 |
| Mar 31, 2024 | 158,000.00 |